Patent: 9,248,115
✉ Email this page to a colleague
Summary for Patent: 9,248,115
Title: | Silibinin component for the treatment of hepatitis |
Abstract: | The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin. |
Inventor(s): | Rovati; Lucio Claudio (Monza, IT), D\'Amato; Massimo Maria (Monza, IT), Mengs; Ulrich (Roesrath, DE), Pohl; Ralf-Torsten (Speyer, DE), Ferenci; Peter (Vienna, AU) |
Assignee: | MADAUS GMBH (Cologne, DE) |
Application Number: | 13/871,045 |
Patent Claims: | see list of patent claims |
Details for Patent 9,248,115
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2027-11-15 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2027-11-15 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2027-11-15 | |
Hoffmann-la Roche Inc. | ROFERON-A | interferon alfa-2a | For Injection | 103145 | 06/04/1986 | ⤷ Try a Trial | 2027-11-15 |
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2027-11-15 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2027-11-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |